Trevi Therapeutics (NASDAQ:TRVI) Earns “Buy” Rating from D. Boral Capital

Trevi Therapeutics (NASDAQ:TRVI)‘s stock had its “buy” rating reiterated by equities researchers at D. Boral Capital in a note issued to investors on Friday,Benzinga reports. They presently have a $21.00 target price on the stock. D. Boral Capital’s price objective indicates a potential upside of 388.37% from the company’s current price.

Several other brokerages have also recently weighed in on TRVI. HC Wainwright boosted their price target on shares of Trevi Therapeutics from $6.00 to $7.50 and gave the stock a “buy” rating in a research report on Thursday, December 12th. Needham & Company LLC reiterated a “buy” rating and set a $8.00 price objective on shares of Trevi Therapeutics in a research report on Thursday, December 12th. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $9.31.

Trevi Therapeutics Stock Performance

Shares of TRVI opened at $4.30 on Friday. The company’s fifty day moving average is $4.14 and its 200 day moving average is $3.51. Trevi Therapeutics has a fifty-two week low of $2.30 and a fifty-two week high of $5.05. The stock has a market capitalization of $330.52 million, a PE ratio of -9.77 and a beta of 0.90.

Institutional Trading of Trevi Therapeutics

A number of hedge funds have recently added to or reduced their stakes in TRVI. Summit Investment Advisors Inc. lifted its stake in Trevi Therapeutics by 84.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company’s stock worth $26,000 after acquiring an additional 2,894 shares during the period. BNP Paribas Financial Markets lifted its stake in Trevi Therapeutics by 130.9% in the third quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock worth $40,000 after acquiring an additional 6,764 shares during the period. Raymond James Financial Inc. purchased a new stake in Trevi Therapeutics in the fourth quarter worth about $49,000. Squarepoint Ops LLC purchased a new stake in Trevi Therapeutics in the fourth quarter worth about $58,000. Finally, Intech Investment Management LLC purchased a new stake in Trevi Therapeutics in the third quarter worth about $63,000. 95.76% of the stock is owned by hedge funds and other institutional investors.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.